AIFM2 and gastric adenocarcinoma: Similar to HCC, the expressions of AIFM2 are also significantly increased in LUAD (Lung adenocarcinoma), STES (Stomach and Esophageal carcinoma), KIRP (Kidney renal papillary cell carcinoma), STAD (Stomach adenocarcinoma), UCEC (Uterine Corpus Endometrial Carcinoma), KICH (Kidney Chromophobe) and CHOL (Cholangiocarcinoma), indicating that AIFM2 may play a crucial oncogenic role in multiple human cancer types.